The sharp reduction in cash burn and operating loss is a positive signal for the company's runway, but the near-total revenue collapse and negative equity highlight the high-risk, pre-revenue nature of the business. Traders should watch for the next collaboration announcement or partnership as the primary catalyst; the current cash position (~$9.3M) provides roughly one year of runway at the guided burn rate, making a future capital raise likely.
Price Chart
Executive Summary
Evogene reported Q2 2026 results showing a sharply reduced net loss of ~$1.8M (vs ~$4.7M in Q2 2025) and guided 2026 cash burn down to ~$8.5-9.5M from ~$14.4M in 2025, driven by its strategic transformation into a lean AI-driven computational chemistry company. However, revenues collapsed 76% YoY in H1 2026 to ~$0.7M due to the wind-down of legacy subsidiaries, and the company remains pre-revenue from its core platform, with equity attributable to holders at negative ~$3.3M. The combination of a drastically lower cost base, six active pharma collaborations, and expanded ChemPass AI platform is offset by a deteriorating revenue base and a cash position of only ~$9.3M, making this a mixed event with a notable but not transformative impact for an $8M market cap stock.
Key Facts
- Q2 2026 net loss reduced to ~$1.8M from ~$4.7M in Q2 2025.
- Full-year 2026 cash burn guided to ~$8.5-9.5M, down from ~$14.4M in 2025.
- H1 2026 revenues fell 76% YoY to ~$0.7M from ~$2.9M.
- Cash and cash equivalents stood at ~$9.3M as of June 30, 2026.
- Workforce reduced from 117 (Dec 2024) to 38 (Aug 2026).
- Six active drug development collaborations established since start of 2026.
- Virtual chemical space expanded to ~110 billion molecules.
- Equity attributable to holders of the company was negative ~$3.3M.
Financial Impact
Q2 net loss improved by ~$2.9M YoY to ~$1.8M; H1 revenue declined ~$2.2M to ~$0.7M; cash burn reduced to ~$2.1M in Q2 2026.
Risk Factors
- Revenue base has nearly evaporated due to subsidiary wind-downs, leaving no recurring revenue from core operations.
- Negative equity attributable to holders (~$3.3M) and reliance on non-controlling interests for total equity signal financial fragility.
- Cash position of ~$9.3M provides limited runway; further dilution from capital raises is probable.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (EVGN) — Batch item 1 | 0001178913-26-004174 |
| Exhibit: exhibit_99-2.htm | 0001178913-26-004174 |
| Document: zk2635981.htm | 0001178913-26-004174 |
| Document: 0001178913-26-004174-index-headers.html | 0001178913-26-004174 |
| Document: 0001178913-26-004174-index.html | 0001178913-26-004174 |
| Document: 0001178913-26-004174.txt | 0001178913-26-004174 |
| 6-K Filing (EVGN) — Batch item 7 | 0001178913-26-004174 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 3 | $0.3641 | awaiting T+60 | — | $0.3466 (−4.81%) |
Oct 6, 2026 20d ago | SC 13D/A | $0.4106 | awaiting T+60 | — | $0.3466 (−15.59%) |
Oct 6, 2026 20d ago | 6-K | $0.4106 | awaiting T+60 | — | $0.3466 (−15.59%) |
Sep 30, 2026 27d ago | 6-K | $0.4000 | awaiting T+60 | — | $0.3466 (+13.35%) |
Sep 30, 2026 27d ago | EFFECT | $0.4000 | awaiting T+60 | — | $0.3466 (+13.35%) |
Sep 4, 2026 7w ago | 6-K | $0.5379 | awaiting T+60 | — | $0.3466 (−35.56%) |
Aug 18, 2026 10w ago | 6-K | $0.5826 | awaiting T+60 | — | $0.3466 (−40.51%) |
Aug 14, 2026 10w ago | Press Release | $0.6008 | awaiting T+60 | — | $0.3466 (−42.31%) |
Jul 31, 2026 12w ago | 6-K | $0.5400 | awaiting T+60 | — | $0.3466 (−35.81%) |
Jun 16, 2026 19w ago | 6-K | $0.5600 $0.4806 | ▼ −14.18% | ▼ −15.18% | $0.3466 (−38.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers